Skip to main content
Richard Delmar Hall

Richard Delmar Hall

Associate Professor of Medicine, Medicine- Hematology and Oncology

Primary Location
UVA Emily Couric Clinical Cancer Center
1240 Lee St.
Charlottesville, VA 22903
Primary Phone Number
Fax Number
434.244.7526

Bio & Overview

Clinical trial design and development for novel therapeutics and immunotherapy for the treatment of lung cancer.

Academic Information

Department
Medicine- Hematology and Oncology

Primary Education

  • Chief Resident, University of Virginianull
  • Clinical Fellowship, Hematology-Oncology, H. Lee Moffitt Cancer Center and Research Institutenull
  • MD, University of Texas Southwestern Medical Centernull
  • MS, Clinical & Translational Research, University of South Floridanull
  • Residency, University of Virginianull

Research Interests

Clinical trial design and development for novel therapeutics and immunotherapy for the treatment of lung cancer.

Selected Publications

2022

Shantzer, L. B., Dougherty, S. C., Bolte, F., Melson, J. W., Reed, D. R., Lynch, A. C., . . . Hall, R. D. (2022). Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report. CLINICAL LUNG CANCER, 24(2), e60-e64. doi:10.1016/j.cllc.2022.11.006

Morris, B. B., Smith, J. P., Zhang, Q., Jiang, Z., Hampton, O. A., Churchman, M. L., . . . Mayo, M. W. (2022). Replicative Instability Drives Cancer Progression. BIOMOLECULES, 12(11). doi:10.3390/biom12111570

Bolte, F. J. J., McTavish, S., Wakefield, N., Shantzer, L., Hubbard, C., Krishnaraj, A., . . . Hall, R. D. D. (2022). Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.986236

2021

Dougherty, S. C., Lynch, A. C., & Hall, R. D. (2021). Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use. CLINICAL CASE REPORTS, 9(6). doi:10.1002/ccr3.4227

2020

Hollen, P. J., Gralla, R. J., Gentzler, R. D., Hall, R. D., Coyne, B., Cheng, H., . . . Lesser, M. (2021). Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. ONCOLOGIST, 26(3), 224-230. doi:10.1002/onco.13571

Dutta, S. W., Mack, M. L., Aliotta, E., Ward, K. A., Muller, D. A., Larner, J. M., . . . Sheehan, J. P. (2020). Intracranial disease control forEGFR-mutant andALK-rearranged lung cancer with large volume or symptomatic brain metastases. JOURNAL OF NEURO-ONCOLOGY, 149(2), 357-366. doi:10.1007/s11060-020-03615-4

Morris, B. B., Wages, N. A., Grant, P. A., Stukenberg, P. T., Gentzler, R. D., Hall, R. D., . . . Mayo, M. W. (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. FRONTIERS IN ONCOLOGY, 10. doi:10.3389/fonc.2020.585551

2019

McLoughlin, E. M., Fadul, C. E., Patel, S. H., Hall, R. D., & Gentzler, R. D. (2019). Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma. JOURNAL OF THORACIC ONCOLOGY, 14(12), E269-E271. doi:10.1016/j.jtho.2019.07.019

Reed, D. R., Hall, R. D., Gentzler, R. D., Volodin, L., Douvas, M. G., & Portell, C. A. (2019). Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(6), E247-E250. doi:10.1016/j.clml.2019.03.001

2018

Volaric, A., Gentzler, R., Hall, R., Mehaffey, J. H., Stelow, E. B., Bullock, T. N., . . . Mills, A. M. (2018). Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 42(9), 1216-1223. doi:10.1097/PAS.0000000000001099

Zaemes, J., Hall, R. D., & Gentzler, R. D. (2018). Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations. JOURNAL OF THORACIC ONCOLOGY, 13(8), E136-E137. doi:10.1016/j.jtho.2018.03.021

2017

Gentzler, R. D., Mohindra, N. A., Hanna, N., Chae, Y. K., Jalal, S. I., Hall, R., . . . Patel, J. D. (2017). Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(1), 236. doi:10.1016/j.ijrobp.2017.01.161

Devitt, M., Hall, R., & Gentzler, R. D. (2017). Peripheral Blood Cell Free DNA to Monitor Mutational Response in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 98(1), 250. doi:10.1016/j.ijrobp.2017.01.197

2016

Gentzler, R., Hall, R., Kunk, P. R., Gaughan, E., Dillon, P., Slingluff, C. L. J., & Rahma, O. E. (2016). Beyond melanoma: inhibiting the PD-1/PDL-1 pathway in solid tumors. IMMUNOTHERAPY, 8(5), 583-600. doi:10.2217/imt-2015-0029

Yang, J. C. -H., Popat, S., Novello, S., Groen, H. J. M., Perol, M., Felip, E., . . . Wakelee, H. A. (2016). TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. JOURNAL OF CLINICAL ONCOLOGY, 34(15). doi:10.1200/JCO.2016.34.15_suppl.TPS9106

2015

Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015). Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). TRANSLATIONAL LUNG CANCER RESEARCH, 4(5), 515-523. doi:10.3978/j.issn.2218-6751.2015.06.09

Smith, M. A., Hall, R., Fisher, K., Haake, S. M., Khalil, F., Schabath, M. B., . . . Haura, E. B. (2015). Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays.. Science signaling, 8(359), ra4. doi:10.1126/scisignal.2005906

2014

Hall, R. D., & Kudchadkar, R. R. (2014). BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. CANCER CONTROL, 21(3), 221-230. doi:10.1177/107327481402100307

2013

Hall, R. D., Gray, J. E., & Chiappori, A. A. (2013). Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.. Cancer control : journal of the Moffitt Cancer Center, 20(1), 22-31. doi:10.1177/107327481302000105